Sandra Pavey
YOU?
Author Swipe
View article: Supplementary Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma
Supplementary Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma Open
Supplementary Figures S1-S3 and Legends; Supplementary Materials and Methods; Supplementary Tables S1-S3.
View article: Supplementary Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma
Supplementary Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma Open
Supplementary Figures S1-S3 and Legends; Supplementary Materials and Methods; Supplementary Tables S1-S3.
View article: Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma
Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma Open
Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection. Within tumor stag…
View article: Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma
Data from Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma Open
Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection. Within tumor stag…
View article: Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Data from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Data from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of antitumor activity seen preclinically and in patients highli…
View article: Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Data from Spontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in <i>Cdk4<sup>R24C/R24C</sup>/TPras</i> Mice
Data from Spontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in <i>Cdk4<sup>R24C/R24C</sup>/TPras</i> Mice Open
Human melanoma susceptibility is often characterized by germ-line inactivating CDKN2A (INK4A/ARF) mutations, or mutations that activate CDK4 by preventing its binding to and inhibition by INK4A. We have previously shown that a single neona…
View article: Data from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Data from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of antitumor activity seen preclinically and in patients highli…
View article: Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figures 1-2, Table 1 from Spontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in <i>Cdk4<sup>R24C/R24C</sup>/TPras</i> Mice
Supplementary Figures 1-2, Table 1 from Spontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in <i>Cdk4<sup>R24C/R24C</sup>/TPras</i> Mice Open
Supplementary Figures 1-2, Table 1 from Spontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in Cdk4R24C/R24C/TPras Mice
View article: Supplementary Figure 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary References from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary References from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary References from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
View article: Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Open
Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)